← Back to Search

Local Anesthetic

1% chloroprocaine for Decreased Discharge Time After Hemorrhoidectomy

Phase 2

Waitlist Available

Led By Iyabo Muse, MD

Research Sponsored by Montefiore Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 160 minutes

Awards & highlights

Study Summary

This trial is testing whether using a higher concentration of a local anesthetic will help patients recover faster and be able to leave the hospital sooner after surgery to remove hemorrhoids.

Eligible Conditions

Decreased Discharge Time After Hemorrhoidectomy
Motor and Sensory Blockade
Spinal Anesthesia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 160 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 160 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 160 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

discharge time (voiding time)

recovery time

Secondary outcome measures

evidence of TNS

evidence of hypotension

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: 1% Chloroprocaine (PF)Experimental Treatment1 Intervention

1% Chloroprocaine is an ester-linked local anesthetic with the shortest duration of action of all local anesthetics.

Group II: 0.75% bupivacaineActive Control1 Intervention

0.75% bupivacaine is a amino-amide anesthetic local anesthetic. It is hyperbaric in nature due to addition of dextrose.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

1% chloroprocaine

2019

Completed Phase 2

~110

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Montefiore Medical CenterLead Sponsor

441 Previous Clinical Trials

582,086 Total Patients Enrolled

Iyabo Muse, MDPrincipal InvestigatorMontefiore Medicial Center

1 Previous Clinical Trials

65 Total Patients Enrolled

Elilary Montilla Medrano, MDPrincipal InvestigatorMontefiore Medicial Center

2 Previous Clinical Trials

99 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you provide information regarding prior investigations of 1% chloroprocaine?

"Currently, there are 110 active investigations into 1% chloroprocaine. Of these studies, 18 have reached Phase 3 of their development process. While the majority of research is taking place in Philadelphia, Pennsylvania, this treatment has been subject to trials at 151 different sites globally."

Answered by AI

Can 1% chloroprocaine be safely administered to patients?

"Drawing on the available evidence, our team at Power rated 1% chloroprocaine as a 2 for safety due to its Phase 2 status. This suggests that while there is some data indicating it can be safely used, no empirical research has been conducted to validate its efficacy yet."

Answered by AI

To what extent is this experiment involving test subjects?

"Indeed, the information hosted on clinicaltrials.gov confirms that this medical trial is actively recruiting patients. It was first published September 6th 2019 and most recently updated September 14th 2022; 60 participants are being sought from a single centre of operations."

Answered by AI

Is enrollment for this experimentation open at present?

"Affirmative. Clinicaltrials.gov attests to this medical trial's ongoing recruitment efforts, which began on September 6th 2019 and were updated as recently as September 14th 2022. This research is seeking 60 test subjects across a single site."

Answered by AI